MRKR
Marker Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.00
P/S
4.29
EV/EBITDA
1973065.38
DCF Value
$1,049,507.82
FCF Yield
-78911210.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-137.3%
Operating Margin
-363.5%
Net Margin
-343.0%
ROE
-0.0%
ROA
-0.0%
ROIC
-0.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.1M | $-1.7M | $-0.10 |
| FY 2025 | $3.5M | $-12.2M | $-0.79 |
| Q3 2025 | $1.2M | $-2.0M | $-0.12 |
| Q2 2025 | $861.2K | $-4.0M | $-0.29 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.47
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.